Prostate Cancer

Positive data released on Neugene antisense technology

Published in Cancer Weekly, July 15th, 2003

AVI BioPharma, Inc., (AVII, AVIIW, AVIIZ) announced that AVI scientists Gayathri R. Devi, PhD, and Adams Amantana, PhD, presented research data describing the successful inhibition of XIAP, one of a family of genes known to inhibit apoptosis, or programmed cell death, in cancer cells using an antisense strategy.

Their presentation was at the 85th Annual Meeting of the Endocrine Society at the Pennsylvania Convention Center in Philadelphia.

The presentation highlighted results from a series of preclinical studies using AVI BioPharma's Neugene antisense technology to block the expression of the gene XIAP. In a wide variety of cancers, including...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-07-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry